HU-014 clinical trials
How each study uses HU-014 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses HU-014 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- To Evaluate HU-014 in the Treatment of Post Stroke Upper LimbCompletedPhase 3Huons Co., Ltd.NCT05289921Written as HU-014 InjHow we know
- A Single Center, Phase I Clinical Trial to Evaluate the Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb SpasticityStatus unknownPhase 1Huons Co., Ltd.NCT04415346Written as HU-014 InjHow we know
- A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet LinesStatus unknownPhase 3Huons Co., Ltd.NCT04081402Written as HU-014How we know
- The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar LinesCompletedPhase 1/2Huons Co., Ltd.NCT02961673Written as HU-014 InjHow we know